Skip to main content

Advertisement

SpringerLink
Log in

miRNA-150 downregulation promotes pertuzumab resistance in ovarian cancer cells via AKT activation

  • Gynecologic Oncology
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Background

Pertuzumab is a humanized mAb that binds to the extracellular region of HER2/ErbB2 and is approved for treating breast cancer. Although ovarian cancer and breast cancer have comparable levels of HER2/ErbB2 expression, clinical studies of pertuzumab in epithelial ovarian cancer patients have not met the same level of success.

Objectives

To investigate the molecular mechanisms by which pertuzumab exerts its anti-tumor effects in ovarian cancer and the mechanisms by which cancer cells achieve pertuzumab resistance.

Methods

We examined expression of miR-150 in ovarian cancer cells treated with pertuzumab or not. miR-150 knockdown impacts on pertuzumab treatment were analyzed by cell proliferation assay, apoptosis analysis and cell cycle analysis. Cell signal pathway was examined by western blot assay.

Results

Pertuzumab induced miRNA-150 expression in SKOV3 and SNU119 cells. Furthermore, suppression of miRNA-150 in both cell lines resulted in decreased drug sensitivity to pertuzumab and cell apoptosis. The blockage of G1/S checkpoint by pertuzumab was rescued as well. miRNA-150 knockdown activated PI3K-Akt pathway and LY294002 reversed the effect of miR-150 knockdown.

Conclusions

miRNA-150 downregulation may contribute to the pertuzumab resistance in ovarian cancer via, at least in part, PI3K-akt pathway.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Siegel RL, Miller KD (2015) Jemal A (2015) Cancer statistics. CA Cancer J Clin 65(1):5–29. doi:10.3322/caac.21254

    Article  PubMed  Google Scholar 

  2. Lengyel E (2010) Ovarian cancer development and metastasis. Am J Pathol 177(3):1053–1064. doi:10.2353/ajpath.2010.100105

    Article  PubMed Central  PubMed  Google Scholar 

  3. Yap TA, Carden CP, Kaye SB (2009) Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 9(3):167–181. doi:10.1038/nrc2583

    Article  CAS  PubMed  Google Scholar 

  4. Tuefferd M, Couturier J, Penault-Llorca F, Vincent-Salomon A, Broet P, Guastalla JP, Allouache D, Combe M, Weber B, Pujade-Lauraine E, Camilleri-Broet S (2007) HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS One 2(11):e1138. doi:10.1371/journal.pone.0001138

    Article  PubMed Central  PubMed  Google Scholar 

  5. Baselga J, Swain SM (2009) Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9(7):463–475. doi:10.1038/nrc2656

    Article  CAS  PubMed  Google Scholar 

  6. Langdon SP, Faratian D, Nagumo Y, Mullen P, Harrison DJ (2010) Pertuzumab for the treatment of ovarian cancer. Exp Opin Biol Ther 10(7):1113–1120. doi:10.1517/14712598.2010.487062

    Article  CAS  Google Scholar 

  7. Metzger-Filho O, Winer EP, Krop I (2013) Pertuzumab: optimizing HER2 blockade. Clin Cancer Res 19(20):5552–5556. doi:10.1158/1078-0432.ccr-13-0518

    Article  CAS  PubMed  Google Scholar 

  8. He L, Hannon GJ (2004) MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5(7):522–531. doi:10.1038/nrg1379

    Article  CAS  PubMed  Google Scholar 

  9. Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6(11):857–866. doi:10.1038/nrc1997

    Article  CAS  PubMed  Google Scholar 

  10. He Y, Jiang X, Chen J (2014) The role of miR-150 in normal and malignant hematopoiesis. Oncogene 33(30):3887–3893. doi:10.1038/onc.2013.346

    Article  CAS  PubMed  Google Scholar 

  11. Warth SC, Hoefig KP, Hiekel A, Schallenberg S, Jovanovic K, Klein L, Kretschmer K, Ansel KM, Heissmeyer V (2015) Induced miR-99a expression represses Mtor cooperatively with miR-150 to promote regulatory T-cell differentiation. EMBO J. doi:10.15252/embj.201489589

    PubMed  Google Scholar 

  12. Jin M, Yang Z, Ye W, Xu H, Hua X (2014) MicroRNA-150 predicts a favorable prognosis in patients with epithelial ovarian cancer, and inhibits cell invasion and metastasis by suppressing transcriptional repressor ZEB1. PLoS One 9(8):e103965. doi:10.1371/journal.pone.0103965

    Article  PubMed Central  PubMed  Google Scholar 

  13. Mraz M, Chen L, Rassenti LZ, Ghia EM, Li H, Jepsen K, Smith EN, Messer K, Frazer KA, Kipps TJ (2014) miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1. Blood 124(1):84–95. doi:10.1182/blood-2013-09-527234

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Valabrega G, Montemurro F, Aglietta M (2007) Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 18(6):977–984. doi:10.1093/annonc/mdl475

    Article  CAS  PubMed  Google Scholar 

  15. Faratian D, Zweemer AJM, Nagumo Y, Sims AH, Muir M, Dodds M, Mullen P, Um I, Kay C, Hasmann M, Harrison DJ, Langdon SP (2011) Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies. Clin Cancer Res 17(13):4451–4461. doi:10.1158/1078-0432.ccr-10-2461

    Article  CAS  PubMed  Google Scholar 

  16. Nakajima H, Mizuta N, Sakaguchi K, Fujiwara I, Yoshimori A, Magae J, Tanuma S (2010) Enhancement of paclitaxel-induced apoptosis in HER2-overexpressing human breast cancer cells by a pertuzumab mimetic peptide,HRAP. J Biosci Bioeng 110(2):250–253. doi:10.1016/j.jbiosc.2010.02.007

    Article  CAS  PubMed  Google Scholar 

  17. Yao E, Zhou W, Lee-Hoeflich ST, Truong T, Haverty PM, Eastham-Anderson J, Lewin-Koh N, Gunter B, Belvin M, Murray LJ, Friedman LS, Sliwkowski MX, Hoeflich KP (2009) Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clin Cancer Res 15(12):4147–4156. doi:10.1158/1078-0432.ccr-08-2814

    Article  CAS  PubMed  Google Scholar 

  18. Gajria D, Chandarlapaty S (2011) HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther 11(2):263–275. doi:10.1586/era.10.226

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Mullen P, Cameron DA, Hasmann M, Smyth JF, Langdon SP (2007) Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling. Mol Cancer Ther 6(1):93–100. doi:10.1158/1535-7163.mct-06-0401

    Article  CAS  PubMed  Google Scholar 

  20. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2(7):489–501. doi:10.1038/nrc839

    Article  CAS  PubMed  Google Scholar 

  21. Greer EL, Brunet A (2005) FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24(50):7410–7425. doi:10.1038/sj.onc.1209086

    Article  CAS  PubMed  Google Scholar 

  22. Wu Y, Shang X, Sarkissyan M, Slamon D, Vadgama JV (2010) FOXO1A is a target for HER2-overexpressing breast tumors. Cancer Res 70(13):5475–5485. doi:10.1158/0008-5472.can-10-0176

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Nahta R, Esteva FJ (2006) Herceptin: mechanisms of action and resistance. Cancer Lett 232(2):123–138. doi:10.1016/j.canlet.2005.01.041

    Article  CAS  PubMed  Google Scholar 

  24. Moasser MM (2007) The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26(45):6469–6487. doi:10.1038/sj.onc.1210477

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Davis R, Singh KP, Kurzrock R, Shankar S (2009) Sulforaphane inhibits angiogenesis through activation of FOXO transcription factors. Oncol Rep 22(6):1473–1478. doi:10.3892/or_00000589

    CAS  PubMed  Google Scholar 

  26. Han J, Pan XY, Xu Y, Xiao Y, An Y, Tie L, Pan Y, Li XJ (2012) Curcumin induces autophagy to protect vascular endothelial cell survival from oxidative stress damage. Autophagy 8(5):812–825. doi:10.4161/auto.19471

    Article  CAS  PubMed  Google Scholar 

  27. Zhou J, Liao W, Yang J, Ma K, Li X, Wang Y, Wang D, Wang L, Zhang Y, Yin Y, Zhao Y, Zhu WG (2012) FOXO3 induces FOXO1-dependent autophagy by activating the AKT1 signaling pathway. Autophagy 8(12):1712–1723. doi:10.4161/auto.21830

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9(8):550–562. doi:10.1038/nrc2664

    Article  CAS  PubMed  Google Scholar 

  29. Fruman DA, Rommel C (2014) PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discovery 13(2):140–156. doi:10.1038/nrd4204

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

We declare that we have no conflict of interest.

Author information

Author notes

    Authors and Affiliations

    1. Department of Gynecology, The First Teaching Hospital of Xinjiang Medical University, No 137 Liyushan South Road, Urumqi, 830054, Xinjiang, People’s Republic of China

      Delinaer Wuerkenbieke, Jing Wang, Yan Li & Cailing Ma

    Authors
    1. Delinaer Wuerkenbieke
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Jing Wang
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Yan Li
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Cailing Ma
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Cailing Ma.

    Additional information

    D. Wuerkenbieke and J. Wang contributed equally.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Wuerkenbieke, D., Wang, J., Li, Y. et al. miRNA-150 downregulation promotes pertuzumab resistance in ovarian cancer cells via AKT activation. Arch Gynecol Obstet 292, 1109–1116 (2015). https://doi.org/10.1007/s00404-015-3742-x

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s00404-015-3742-x

    Keywords

    Search

    Navigation